Genome & Company Signs a Clinical Trial Agreement with Merck KGaA and Pfizer to Evaluate the Combination Therapy

 Genome & Company Signs a Clinical Trial Agreement with Merck KGaA and Pfizer to Evaluate the Combination Therapy

Genome & Company Signs a Clinical Trial Agreement with Merck KGaA and Pfizer to Evaluate the Combination Therapy

Shots:

  • Genome & Company enters into a clinical trial and supply agreement with Merck KGaA and Pfizer to evaluate the safety, tolerability, biological and clinical activities of GEN-001 + Bavencio (avelumab) for multiple cancer indications
  • Genome & Company will sponsor the study while Merck KGaA will supply avelumab in P-I/Ib study which is expected to be initiated in 2020 in the US. Both parties will have access to the clinical data
  •  GEN-001 is an oral microbiome therapy developed to have immune-modulating activities and has demonstrated synergistic effect with an immune checkpoint inhibitor to suppress the growth of both immune checkpoint inhibitor sensitive and resistant tumor models

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Genome & Company

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post